Online inquiry

IVTScrip™ mRNA-Anti-B4GALNT1, Hu3F8(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ8527MR)

This product GTTS-WQ8527MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets B4GALNT1 gene. The antibody can be applied in Neuroblastoma research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Chimeric
RefSeq NM_001276468.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2583
UniProt ID Q00973
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-B4GALNT1, Hu3F8(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ8527MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6273MR IVTScrip™ mRNA-Anti-HA, CR-6261(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA CR-6261
GTTS-WQ10565MR IVTScrip™ mRNA-Anti-IL23A, LY­3074828(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA LY­3074828
GTTS-WQ3598MR IVTScrip™ mRNA-Anti-LYPD3, BAY 1129980(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BAY 1129980
GTTS-WQ14147MR IVTScrip™ mRNA-Anti-IL6R, aIL6R88(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA aIL6R88
GTTS-WQ10754MR IVTScrip™ mRNA-Anti-ADAMTSL5&ALB, M-6495(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA M-6495
GTTS-WQ10830MR IVTScrip™ mRNA-Anti-PD-L1&TGFBR2, M7824(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA M7824
GTTS-WQ10018MR IVTScrip™ mRNA-Anti-FGF23, KRN-23(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA KRN-23
GTTS-WQ1749MR IVTScrip™ mRNA-Anti-IL2RA, ADCT-301(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ADCT-301
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW